BioNTech co-founders Uögur Şahin and Özlem İüretı are departing the German biotech giant to establish their own mRNA-focused company, according to Financial Times Companies. The move signals a potential shift in leadership for the firm that pioneered the first widely used COVID-19 vaccine. While BioNTech's board will oversee the transition, analysts note this could accelerate innovation in mRNA therapeutics.

The founders' departure may create opportunities for new competitors in the rapidly evolving mRNA space. BioNTech confirmed the resignations, stating the founders will focus on developing novel mRNA technologies. mRNA therapeutics represent a $50 billion market expected to grow significantly. This strategic pivot could reshape the industry's competitive landscape.